{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"57","value":"29.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"}],"units":"Participants"}],"description":"Ctrough is the concentration at the end of the dosing interval when avelumab was given as a Q2W regimen in the absence of carboplatin and paclitaxel following 1 cycle of avelumab dosing, i.e. before administration of drug on Day 1 of cycle 2. Ctrough of Avelumab in the absence of chemotherapy (i.e. in the maintenance phase) has been reported. The LLQ of avelumab was 0.20 micro-gram per milliliter (mcg/mL). Data for this outcome measure was not reported for reporting arms \"PK: Chemotherapy + Avelumab followed by Avelumab\" (since data was not planned to be collected 1 cycle after the initiation of avelumab dosing ) and \"PK: Chemotherapy followed by Observation\" (since avelumab was not administered in this arm and therefore data collection was not planned).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"In chemotherapy phase, participants received paclitaxel Q3W (or QW on Days 1, 8 and 15), followed by carboplatin Q3W on Day 1 of each 21 day cycle for 6 cycles. During the maintenance phase, participants received avelumab Q2W on Days 1, 15 and 29 of each 42 day cycle.","id":"OG000","title":"PK: Chemotherapy Followed by Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Avelumab PK concentration analysis set included all participants who had received at least one dose of study drug and who had at least one post-dose concentration measurement above the LLQ for avelumab. Here \"Overall number of participants analyzed\" signifies participants who had data available for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hour) on Day 1 of Cycle 2","title":"Maintenance Phase: Predose Plasma Concentration (Ctrough) of Avelumab","type":"SECONDARY","unitOfMeasure":"mcg/mL"}